SNYR Spending and interest coverage

Synergy CHC Corp. (SNYR) Spending and interest coverage

R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..

Spending and interest coverage

Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.

Metric	Value	Formula and calculation
R&D / revenue · 12 months	(m)	Research and development expense / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m).
Stock-based compensation / revenue · 12 months	(m)	Share-based compensation / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m).
Interest coverage · 12 months	(m)	Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m).

Calculation inputs

Input	Amount with unit	Raw financial data
Research and development spending	(m)
Revenue	27.70M USD	Revenue from Contract with Customer, Excluding Assessed Tax
Stock-based compensation	(m)	Share-based Payment Arrangement, Noncash Expense
Operating income	-10.97M USD	Operating Income (Loss)
Interest expense · reported / estimated	(m)	Interest Expense · Estimated expense assumptions

Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period ending	Research and development spending (USD)	Revenue (USD)	Stock-based compensation (USD)	Operating income (USD)	Interest expense · reported / estimated (USD)	R&D / revenue	SBC / revenue	Interest coverage	Interest expense basis
2026-03-31	(m)	$27.70M	(m)	$-10.97M	(m)	(m)	(m)	(m)	(m)
2025-12-31	(m)	$30.38M	$136.25K	$-8.46M	(m)	(m)	0.45%	(m)	(m)
2025-09-30	(m)	$34.59M	(m)	$6.21M	(m)	(m)	(m)	(m)	(m)
2025-06-30	(m)	$33.70M	(m)	$5.98M	(m)	(m)	(m)	(m)	(m)
2025-03-31	(m)	$33.59M	(m)	$5.94M	$1.50M	(m)	(m)	3.96×	Reported
2024-12-31	(m)	$34.83M	(m)	$5.80M	$1.55M	(m)	(m)	3.75×	Reported
2024-09-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-06-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-03-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-12-31	(m)	$42.78M	(m)	$10.81M	$1.69M	(m)	(m)	6.38×	Reported
2023-09-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	(m)	$26.01M	$154.72K	$-8.77M	(m)	(m)	0.59%	(m)	(m)
2019-12-31	(m)	$29.36M	$201.16K	$-7.96M	(m)	(m)	0.69%	(m)	(m)
2019-09-30	(m)	$28.37M	$454.49K	$-3.00M	(m)	(m)	1.60%	(m)	(m)
2019-06-30	(m)	$30.20M	$325.41K	$-2.72M	(m)	(m)	1.08%	(m)	(m)
2019-03-31	(m)	$33.59M	$406.50K	$-3.52M	(m)	(m)	1.21%	(m)	(m)
2018-12-31	(m)	$33.82M	$441.00K	$-4.92M	$1.13M	(m)	1.30%	-4.34×	Reported
2018-09-30	(m)	$34.93M	$583.21K	$-719.39K	$-886.69K	(m)	1.67%	(m)	Reported
2018-06-30	(m)	$34.92M	$1.02M	$-914.05K	$-902.86K	(m)	2.91%	(m)	Reported
2018-03-31	(m)	$34.51M	$1.24M	$-910.41K	$-1.07M	(m)	3.59%	(m)	Reported
2017-12-31	(m)	$35.60M	$1.46M	$1.82M	$-1.04M	(m)	4.10%	(m)	Reported
2017-09-30	(m)	$36.01M	$2.31M	$-1.05M	$-1.01M	(m)	6.42%	(m)	Reported
2017-06-30	(m)	$38.41M	$2.27M	$1.43M	$-1.17M	(m)	5.92%	(m)	Reported
2017-03-31	(m)	$37.36M	$2.24M	$3.46M	$-1.38M	(m)	5.99%	(m)	Reported
2016-12-31	(m)	$34.84M	$2.20M	$2.93M	$-1.57M	(m)	6.31%	(m)	Reported
2016-09-30	(m)	$34.33M	$1.44M	$7.77M	$-1.61M	(m)	4.19%	(m)	Reported
2016-06-30	(m)	$25.94M	$1.13M	$4.92M	$-1.39M	(m)	4.38%	(m)	Reported
2016-03-31	(m)	$20.12M	$842.36K	$3.25M	$-698.87K	(m)	4.19%	(m)	Reported
2015-12-31	(m)	$13.46M	$551.71K	$486.02K	$-958.74K	(m)	4.10%	(m)	Reported
2015-09-30	(m)	$7.24M	$40.00K	(m)	(m)	(m)	0.55%	(m)	(m)
2015-06-30	(m)	$4.06M	$49.00K	(m)	(m)	(m)	1.21%	(m)	(m)
2015-03-31	(m)	$1.61M	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	(m)	$9.16K	$322.25K	(m)	$2.00K	(m)	3518.75%	(m)	Reported
2014-09-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-06-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-03-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-01-31	(m)	(m)	(m)	(m)	$1.56K	(m)	(m)	(m)	Reported
2013-12-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-07-31	(m)	(m)	(m)	(m)	$1.42K	(m)	(m)	(m)	Reported
2013-06-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-03-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-01-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-12-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-07-31	(m)	(m)	(m)	(m)	$1.20K	(m)	(m)	(m)	Reported
2011-07-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Functional Brands Inc. (MEHA)	United States	$0.001B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)	United States	$0.011B	-1.16
MANNATECH INC (MTEX)	United States	$0.014B
FITLIFE BRANDS, INC. (FTLF)	United States	$0.087B	16.59
Niagen Bioscience, Inc. (NAGE)	United States	$0.238B	15.72
USANA HEALTH SCIENCES INC (USNA)	United States	$0.264B	-17.90
Canopy Growth Corp (CGC)		$0.395B
Tilray Brands, Inc. (TLRY)	United States	$0.554B	-5.97
Cronos Group Inc. (CRON)		$1.223B
Definium Therapeutics, Inc. (DFTX)	United States	$4.931B	-17.87